When it comes to securing science-based evidence of safety and efficacy for your compound or formulation, InVivo has you covered. With our preclinical platform, RapidGen™, we specialize in working with the pharmaceutical, nutraceutical, and biotech industries, offering a wide range of analytical assays, including the miniaturization of cell-based assays and the utilization of reporter cell lines. These approaches allow us to provide critical data, including the response of living cells to your compounds, ensuring comprehensive and reliable results. With our unique workflows and capabilities, we can deliver the data you require, delivering benefits to your business in as little as 3 months.
More from the RapidGen™ Platform
Get your efficacy and safety data in as little as 3 months
Need comprehensive science-based evidence of safety and efficacy for your compound or formulation? We are a preclinical CRO and work with pharmaceutical, nutraceutical, and biotech industries by providing the data our clients need to select the most effective “winning” compounds, determine mechanism of action, file patents and succeed in clinical trials.
Learn how we support Thaena Inc. to develop novel metabolite research platform in this Press Release.
Our unique workflows and capabilities can deliver the data you need and benefits to your business in as little as 3 months.
Listen to one of our customers (Mikra) discuss why they chose to partner with us and the value they gained from working with our team >>
“We were able to get the data we needed to proceed with product development within our timeline and budget. We trust the data and findings provided by InVivo Biosystems, which are shared with our customers and distributors. I really felt that InVivo Biosystems did pretty much everything that they said they would do. It was done in a manner that gave me confidence in the results.”
– Dr. David Vollmer, Chief Scientific Officer, 4Life Research.
We perform lifetime monitoring of a large population animals to determine whether compounds and formulations affect lifespan and healthspan.
We uncover whether a compound or formulation has antioxidant properties using a standardized reactive oxygen species exposure assay.
We utilize cutting-edge RNAseq and transcriptomics technology to reveal how compounds impact gene expression by analyzing up or down-regulated genetic pathways.
We investigate the impact of a compound or formulation on mitochondrial function across the lifespan utilizing fluorescent imaging of mitochondrial structures.
We determine the role of the underlying genetics in creating health benefits and investigate the underlying mechanisms involved in pathway.
Our data helps companies prioritize their development pipelines by giving them quantitative information about how candidate formulations combat aging and age-related conditions.
Traditional longevity experiments using mice can take upwards of 2-3 years to complete and cost hundreds of thousands of dollars. Using our platform, you can quickly and economically test a compound’s ability to extend lifespan and healthspan with large sample sizes of live animals in less than 5 months and get answers to the following questions:
Get Kaplan-Meier survival curves from live animals within 5 months.
Using our platform, you can quickly and economically test a compound’s ability to extend lifespan and healthspan with large sample sizes of live animals. We use automated scanning to produce smooth, high resolution survival curves and ensure reproducibility, detection power, high resolution and robust conclusions.
Aging pathway analysis. Global gene expression analysis indicates two candidate pathways likely to mediate the effect of compound on lifespan: oxidative phosphorylation and oxidative stress.
Leverage Molecular Biology to Understand Mechanism of Action.
We use RNAseq to help our clients get the “big picture” effect of their compound on known aging pathways including mitochondrial stress, oxidative stress, and DNA damage. By comparing the complete gene expression profile of animals as they age, we can uncover how compounds exert their lifespan-extending effects.
Mapping of gene expression data to longevity pathways in the KEGG database. Pathway shown represents changes of expression that might be observed under conditions of dietary restriction. Pathway components are color coded based on the level of up or down regulation of treated samples versus control.
Step I: Dose Finding
Viability, Growth and Development Assay to determine toxicity of Lu0128 in C. elegans.
Left: Violin plot showing distribution of worm lengths during development from larvae to adult when treated with varying concentrations of Lu0128. Right: Day 3 snapshot of worm development including embryonic lethality (black).
Step II: Measuring lifespan
Measure the lifespan and vitality extending effects of the compound by monitoring the adult animal’s survival, morphology and motility. The healthspan metrics are extracted from the same dataset as the lifespan readings.
Step III: Identifying Aging Pathways
Identify the aging pathways that contribute to the observed lifespan extension from Step II. Potentially identified pathways and mechanisms are identified, including genes related to mTOR, sirtuin, dietary restriction, oxidative stress.
Mapping of gene expression data to longevity pathways in the KEGG database.
Pathway shown represents changes of expression that might be observed under conditions of dietary restriction. Pathway components are color coded based on the level of up or down regulation of treated samples versus control.
Measure changes in gene expression level.
The gene asp-12 is downregulated 117-fold (p=1.3e-37) in the day 10 Lu0128 treated samples compared with the day 10 untreated. The gene lea-1 is upregulated 6.5-fold (p=2.4e-16) in the day 10 Lu0128 treated samples compared with the day 10 untreated.
Data Only
Data Interpretation
Data Customization
Timeline
2-3 months
2-3 months
2-3 months
Study Report
Vitality & Antioxidant Study Report – an example of a client project report.
We monitor and measure the growth rate of animals exposed to compound from hatching to the first day of adulthood (total of 4 days) using precise, automated image analysis. Nematode growth rate and development is highly sensitive to chemical disturbances, and the growth assay is widely used in toxicology studies.
WTS can be more cost-effective than qPCR to identify which genomic loci are expressed in a population at a given time over the entire expression range, hypothesis-free (without the need to pre-define the genes of interest). In addition, WTS yields high dimensional data for a large number of genomic loci and detects gene expression changes (i.e., mRNA levels) between different experimental conditions.
We accept crystals, solutions, emulsions, oils, natural extracts, nanoparticles or nanobeads up to 15 µm diameter.
We do not accept compounds that are hazardous and/or BSL 3 and above or any hazardous volatile compounds that require handling in a chemical hood.
Yes, however we recommend that a client provide either the compound itself or the specific catalog number(s) of the compound to be tested.
A positive and a negative control are included for each compound. The appropriate controls will be defined based on the nature of the compounds to be tested.
Introduction
We will set up a 30-minute call with you to understand your needs. During this call, we will define the scope of your project, answer your practical questions and help you assess whether our service is a good fit for you.
01
02
Design
After we decide on the scope of the project, we will create a proposal that includes cost and time estimate for each experiment proposed. You will be able to personalize your project plan.
Logistics
We will send you a final statement of work and payment schedule. Once we receive your first PO, we will start the experiments and give you a defined timeline for your project.
03
Report Out
We will keep you updated every two weeks on the status of your project. At the end of your project, we provide you with a report that includes comprehensive findings and key takeaways.
04
Ready to get started?
Ready to connect with us to learn more about working with our company or our technology?
Submit your inquiry below & we will get back to you soon.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.
